This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Investing in Phibro (PAHC)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Explore Phibro's (PAHC) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
AMED Q3 Earnings and Revenues Miss, Margins Dip, Stock Falls
by Zacks Equity Research
Amedisys, for the third quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View
by Zacks Equity Research
Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company increases its full-year EPS guidance.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
by Zacks Equity Research
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
PAHC or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. ABT: Which Stock Is the Better Value Option?
BRKR Misses on Q3 Earnings, Cuts '24 View, Stock Up in Aftermarket
by Zacks Equity Research
Bruker delivers robust revenue growth in the third quarter despite soft general market conditions.
STE Q2 Earnings Beat Estimates, Margins Dip, Stock Gains in Aftermarket
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of both margins is concerning.
Phibro's Q1 Earnings Top Estimates, Stock Up, Net Sales Surge Y/Y
by Zacks Equity Research
PAHC delivers strong growth across all its segments in the first quarter of fiscal 2025.
Zacks.com featured highlights include IAMGOLD, Leidos, Brinker International, Phibro Animal Health and State Street
by Zacks Equity Research
AMGOLD, Leidos, Brinker International, Phibro Animal Health and State Street are part of the Zacks Screen of the Week article.
Phibro (PAHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Phibro Animal Health (PAHC) Tops Q1 Earnings Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 52.17% and 6.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like IAG, LDOS, EAT, PAHC and STT are seeing price strength and have a high chance of carrying the momentum forward.
GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket
by Zacks Equity Research
Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket
by Zacks Equity Research
Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.
ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket
by Zacks Equity Research
Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.
AdaptHealth Corp. (AHCO) Surpasses Q3 Earnings Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of 5% and 0.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain DGX Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
by Zacks Equity Research
IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up
by Zacks Equity Research
Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.